CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

CVRx, Inc. (NASDAQ: CVRX), a notable player in the medical device industry specializing in neuromodulation solutions for cardiovascular diseases, has announced its plans to disclose its financial and operational results for the fourth quarter of 2025. The results will be shared after market close on February 12, 2026. Following the release, CVRx will host a conference call at 4:30 p.m. Eastern Time to discuss these results in detail. Interested parties can join the live webcast of the conference call via the investor relations section of CVRx's website or participate by phone using designated dialing numbers for U.S. and international callers.

CVRx is particularly recognized for its flagship product, Barostim™, which is the first FDA-approved medical technology employing neuromodulation as a treatment for heart failure. This innovative implantable device works by delivering electrical impulses to baroreceptors in the carotid artery's wall, aiming to rebalance the autonomic nervous system and alleviate heart failure symptoms. Barostim has notably received the FDA Breakthrough Device designation, emphasizing its promise and potential in the cardiovascular medical field. It is also certified under the EU Medical Device Regulation (MDR) and holds a CE Mark for its applications in heart failure and resistant hypertension within the European Economic Area.

Investors and stakeholders eager for insights into CVRx’s performance and future direction are encouraged to tune into the forthcoming conference call, which promises to provide valuable information on the company's endeavors and progress in addressing cardiovascular diseases with their advanced technologies.

As CVRx, Inc. (NASDAQ: CVRX) prepares to report its fourth quarter 2025 financial results on February 12, 2026, investors should focus on several key indicators that could influence the stock's performance. With the innovative Barostim™ device paving the way for CVRx in the neuromodulation space, the market will be keenly analyzing the company’s revenue growth, particularly in relation to the adoption and sales of Barostim.

Given that Barostim is the first FDA-approved neuromodulation therapy for heart failure, the quarterly results should reflect how well it has penetrated the market. Analysts will be looking for details on sales figures, potential new partnerships, and any shifts in market dynamics, such as competition or regulatory changes. CVRx’s ability to expand internationally, particularly in regions where Barostim has received CE Mark certification, will also be a critical component of revenue generation.

Investors should note any guidance offered for the upcoming fiscal year. Strong forward guidance may signal confidence in growth projections and could lead to upward revisions in analysts’ ratings. Conversely, if results fall short of expectations, particularly in sales or operational metrics, the company may face stock price volatility.

Additionally, CVRx's research and development pipeline and any forthcoming clinical trial results could provide further insights into the company's long-term sustainability and growth prospects. Engaging in the conference call could offer valuable context around these results and management’s strategic priorities.

In conclusion, while CVRx has established a unique position within the cardiovascular treatment landscape, market participants should approach the earnings release with an understanding of both current performance and future potential. Close monitoring of how management communicates its results and outlook will be crucial for making informed investment decisions.